• Mashup Score: 2
    VERTIS CV: Ertugliflozin reduces HF events in diabetes, ASCVD - 4 year(s) ago

    Among patients with type 2 diabetes and atherosclerotic CVD, the SGLT2 inhibitor ertugliflozin reduced risk for first and total HF events compared with placebo, according to new data from the VERTIS CV study. As Healio previously reported, in the main results of VERTIS CV, patients with type 2 diabetes and established ASCVD had similar risk for CV events at 3.5 years whether assigned

    Source: www.healio.com
    Categories: Cardiology News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of CardiologyToday
      CardiologyToday

      VERTIS CV: Among patients with type 2 diabetes and ASCVD, the SGLT2 inhibitor #ertugliflozin reduced risk for first and total HF events compared with placebo #ESCCongress @ESCardio @ESCardioNews #cardiotwitter @karolinskainst @EndocrineToday https://t.co/JWZ5qLqVw7

  • Mashup Score: 0
    VERTIS-CV: Ertugliflozin CV neutral, benefit seen in type 2 diabetes - 4 year(s) ago

    Adults with type 2 diabetes and established atherosclerotic cardiovascular disease were no more likely to experience a CV event during 3.5 years of follow-up with the SGLT2 inhibitor ertugliflozin compared with placebo, study data show.In presenting findings from VERTIS-CV trial, a randomized controlled trial with more than 8,200 participants from 34 countries, researchers also said participants

    Source: www.healio.com
    Categories: General Medicine News, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of GoHealio
      GoHealio

      VERTIS-CV: Ertugliflozin CV neutral, heart failure benefit seen in type 2 #diabetes. @cpcannon #ADAGoesVirtual, #ADA2020 #ertugliflozin https://t.co/pRvbC9IhxS

    • Profile photo of EndocrineToday
      EndocrineToday

      VERTIS-CV: Ertugliflozin CV neutral, heart failure benefit seen in type 2 #diabetes. @cpcannon #ADAGoesVirtual, #ADA2020 #ertugliflozin https://t.co/mpk7ODUfuf